Estrella Immunopharma Inc (ESLA)

Currency in USD
0.823
-0.046(-5.27%)
Real-time Data·
ESLA Scorecard
Full Analysis
Suffers from weak gross profit margins
ESLA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.8230.830
52 wk Range
0.6301.780
Key Statistics
Prev. Close
0.842
Open
0.83
Day's Range
0.823-0.83
52 wk Range
0.63-1.78
Volume
7.66K
Average Volume (3m)
179.07K
1-Year Change
-39.21%
Book Value / Share
-0.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ESLA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.000
Upside
+1,844.11%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Estrella Immunopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Estrella Immunopharma Inc Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.

Compare ESLA to Peers and Sector

Metrics to compare
ESLA
Peers
Sector
Relationship
P/E Ratio
−2.9x−4.6x−0.5x
PEG Ratio
−0.030.010.00
Price/Book
−16.6x2.7x2.6x
Price / LTM Sales
-151.9x3.3x
Upside (Analyst Target)
-179.1%43.4%
Fair Value Upside
Unlock2.5%7.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.000
(+1,844.11% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.06 / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ESLA Income Statement

People Also Watch

257.93
AVAV
-0.65%
37.42
EXEL
+0.07%
97.03
ZBH
-1.42%
0.400
CLSD
+4.44%
15.77
ARWR
-1.81%

FAQ

What Stock Exchange Does Estrella Immunopharma Trade On?

Estrella Immunopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Estrella Immunopharma?

The stock symbol for Estrella Immunopharma is "ESLA."

What Is the Estrella Immunopharma Market Cap?

As of today, Estrella Immunopharma market cap is 30.45M.

What Is Estrella Immunopharma's Earnings Per Share (TTM)?

The Estrella Immunopharma EPS (TTM) is -0.29.

From a Technical Analysis Perspective, Is ESLA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Estrella Immunopharma Stock Split?

Estrella Immunopharma has split 0 times.

How Many Employees Does Estrella Immunopharma Have?

Estrella Immunopharma has 0 employees.

What is the current trading status of Estrella Immunopharma (ESLA)?

As of 08 Aug 2025, Estrella Immunopharma (ESLA) is trading at a price of 0.82, with a previous close of 0.84. The stock has fluctuated within a day range of 0.82 to 0.83, while its 52-week range spans from 0.63 to 1.78.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.